Dr Reddys Laboratories' subsidiary files lawsuit for patent infringement in US

Image
Capital Market
Last Updated : May 25 2018 | 6:50 PM IST
Dr Reddys Laboratories announced that its subsidiary, Promius Pharma LLC has filed a lawsuit for patent infringement in the United States District Court for Eastern District of Texas against Perrigo UK FINCO Limited Partnership, Perrigo Israel Pharmaceuticals, and Taro Pharmaceuticals, Inc. in response to two paragraph-IV notice letters received for its twice daily topical spray SERNIVO (betamethasone dipropionate, 0.05%) product. Promius anticipates this lawsuit will trigger a 30 month stay of FDA approval of Perrigo's and Taro's ANDAs.

SERNIVO spray, 0.05% is protected by six Orange Book patents that expire in 2030. Promius will continue to vigorously defend its SERNIVO intellectual property rights against infringement wherever they are challenged

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 25 2018 | 6:17 PM IST

Next Story